Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts

Blood

Volumn 127, Issue 23, 2016, Pages 2879-2889

  Vasu, Sumithira ^a   He, Shun ^a   Cheney, Carolyn ^a   Gopalakrishnan, Bhavani ^a   Mani, Rajeswaran ^a   Lozanski, Gerard ^a   Mo, Xiaokui ^b   Groh, Veronica ^c   Whitman, Susan P ^a   Konopitzky, Renate ^d   Kössl, Christian ^d   Bucci, Donna ^a   Lucas, David M ^a   Yu, Jianhua ^a   Caligiuri, Michael A ^a   Blum, William ^a   Adam, Paul J ^d   Borges, Eric ^d   Rueter, Bjoern ^e   Heider, Karl Heinz ^d   Marcucci, Guido ^f   Muthusamy, Natarajan ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; AZACITIDINE; BI 836854; BI 836858; CD3 ANTIGEN; CD33 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; DECITABINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 3; LINTUZUMAB; MESSENGER RNA; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; STEM CELL FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD33 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; ASPIRATION; BONE MARROW; BONE MARROW BIOPSY; CELL ACTIVATION; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONTROLLED STUDY; DEGRANULATION; DRUG EFFICACY; HL 60 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; UPREGULATION; ANALOGS AND DERIVATIVES; CELL CULTURE; CYTOTOXICITY; DRUG EFFECTS; DRUG POTENTIATION; HL-60 CELL LINE; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; MULTIMODALITY CANCER THERAPY;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DRUG SYNERGISM; HL-60 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; RECOMBINANT PROTEINS; SIALIC ACID BINDING IG-LIKE LECTIN 3;

EID: 84993661822     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-680546     Document Type: Article

References (37)

1. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916-1924.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
3. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25(14):1908-1915.
4. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood. 1986;67(4):1048-1053.
5. Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia. 2000;14(3):474-475.
6. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005;19(2):176-182.
7. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26):6198-6208.
8. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854-4860.
9. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30(32):3924-3931.
10. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986-996.
11. Raza A, Jurcic JG, Roboz GJ, et al. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymphoma. 2009;50(8):1336-1344.
12. Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23(18):4110-4116.
13. Romain G, Senyukov V, Rey-Villamizar N, et al. Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood. 2014;124(22):3241-3249.
14. Gleason MK, Ross JA, Warlick ED, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 2014;123(19):3016-3026.
15. Chretien AS, Le Roy A, Vey N, et al. Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front Immunol. 2014;5:122.
16. Stringaris K, Sekine T, Khoder A, et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014;99(5):836-847.
17. Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipowicz A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res. 2007;31(10):1393-1402.
18. Tang KF, He CX, Zeng GL, et al. Induction of MHC class I-related chain B (MICB) by 5-aza-2′-deoxycytidine. Biochem Biophys Res Commun. 2008;370(4):578-583.
19. Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature. 1994;368(6474):856-859.
20. Heider KH, Kiefer K, Zenz T, et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood. 2011;118(15):4159-4168.
21. Kossman SE, Scheinberg DA, Jurcic JG, Jimenez J, Caron PC. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. Clin Cancer Res. 1999;5(10):2748-2755.
22. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294(1-2):15-22.
23. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734-738.
24. Geert V, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York, NY: Springer; 2000.
25. Hsu J. Multiple Comparisons: Theory and Methods. Boca Raton, FL: CRC Press; 1996.
26. Zhuravleva MA, Trandem K, Sun PD. Structural implications of Siglec-5-mediated sialoglycan recognition. J Mol Biol. 2008;375(2):437-447.
27. Bühring HJ, Sures I, Jallal B, et al. The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood. 1995;86(5):1916-1923.
28. Peiper SC, Ashmun RA, Look AT. Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood. 1988;72(1):314-321.
29. Jurcic JG. What happened to anti-CD33 therapy for acute myeloid leukemia? Curr Hematol Malig Rep. 2012;7(1):65-73.
30. Sutherland MK, Yu C, Lewis TS, et al. Antileukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs. 2009;1(5):481-490.
31. Rogers KA, Jones JA. Obinutuzumab for the treatment of chronic lymphocytic leukemia. Drugs Today (Barc). 2014;50(6):407-419.
32. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562-569.
33. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-2677.
34. Quintás-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120(24):4840-4845.
35. Schmiedel BJ, Arelin V, Gruenebach F, Krusch M, Schmidt SM, Salih HR. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer. 2011;128(12):2911-2922.
36. Kopp LM, Ray A, Denman CJ, et al. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. Mol Immunol. 2013;54(3-4):296-301.
37. Hilpert J, Grosse-Hovest L, Grünebach F, et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol. 2012;189(3):1360-1371.